nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—AOX1—Raloxifene—osteoporosis	0.246	0.295	CbGbCtD
Pyrazinamide—AOX1—Ethinyl Estradiol—osteoporosis	0.237	0.285	CbGbCtD
Pyrazinamide—AOX1—Estradiol—osteoporosis	0.153	0.183	CbGbCtD
Pyrazinamide—CYP1A2—Estropipate—osteoporosis	0.0414	0.0497	CbGbCtD
Pyrazinamide—CYP3A4—Estropipate—osteoporosis	0.0217	0.026	CbGbCtD
Pyrazinamide—CYP3A4—Calcitriol—osteoporosis	0.0217	0.026	CbGbCtD
Pyrazinamide—CYP1A2—Conjugated Estrogens—osteoporosis	0.0196	0.0235	CbGbCtD
Pyrazinamide—CYP3A4—Ergocalciferol—osteoporosis	0.0174	0.0208	CbGbCtD
Pyrazinamide—CYP1A2—Estradiol—osteoporosis	0.0172	0.0206	CbGbCtD
Pyrazinamide—CYP3A4—Raloxifene—osteoporosis	0.0145	0.0174	CbGbCtD
Pyrazinamide—CYP3A4—Ethinyl Estradiol—osteoporosis	0.014	0.0168	CbGbCtD
Pyrazinamide—CYP3A4—Cholecalciferol—osteoporosis	0.0112	0.0134	CbGbCtD
Pyrazinamide—CYP3A4—Conjugated Estrogens—osteoporosis	0.0103	0.0123	CbGbCtD
Pyrazinamide—CYP3A4—Estradiol—osteoporosis	0.00902	0.0108	CbGbCtD
Pyrazinamide—XDH—Purine catabolism—PNP—osteoporosis	0.00833	0.183	CbGpPWpGaD
Pyrazinamide—Porphyrin metabolism disorder—Estropipate—osteoporosis	0.00791	0.0654	CcSEcCtD
Pyrazinamide—Porphyrin metabolism disorder—Conjugated Estrogens—osteoporosis	0.00523	0.0432	CcSEcCtD
Pyrazinamide—Porphyrin metabolism disorder—Estradiol—osteoporosis	0.00418	0.0346	CcSEcCtD
Pyrazinamide—XDH—Purine metabolism—ATIC—osteoporosis	0.0032	0.0705	CbGpPWpGaD
Pyrazinamide—XDH—Purine metabolism—PNP—osteoporosis	0.0032	0.0705	CbGpPWpGaD
Pyrazinamide—Clotting—Conjugated Estrogens—osteoporosis	0.00307	0.0254	CcSEcCtD
Pyrazinamide—Peptic ulcer—Etidronic acid—osteoporosis	0.00287	0.0237	CcSEcCtD
Pyrazinamide—Clotting—Estradiol—osteoporosis	0.00245	0.0203	CcSEcCtD
Pyrazinamide—XDH—Purine catabolism—GPX1—osteoporosis	0.00236	0.0519	CbGpPWpGaD
Pyrazinamide—Rash maculo-papular—Etidronic acid—osteoporosis	0.00174	0.0144	CcSEcCtD
Pyrazinamide—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00168	0.037	CbGpPWpGaD
Pyrazinamide—Tubulointerstitial nephritis—Pamidronate—osteoporosis	0.00163	0.0134	CcSEcCtD
Pyrazinamide—XDH—Nucleotide metabolism—ATIC—osteoporosis	0.00161	0.0354	CbGpPWpGaD
Pyrazinamide—XDH—Nucleotide metabolism—PNP—osteoporosis	0.00161	0.0354	CbGpPWpGaD
Pyrazinamide—Coagulopathy—Pamidronate—osteoporosis	0.0016	0.0132	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—PRDX3—osteoporosis	0.0016	0.0352	CbGpPWpGaD
Pyrazinamide—Coagulopathy—Zoledronate—osteoporosis	0.00146	0.0121	CcSEcCtD
Pyrazinamide—Coagulopathy—Conjugated Estrogens—osteoporosis	0.00141	0.0116	CcSEcCtD
Pyrazinamide—Photosensitivity—Alendronate—osteoporosis	0.00135	0.0112	CcSEcCtD
Pyrazinamide—Coagulopathy—Estradiol—osteoporosis	0.00113	0.00931	CcSEcCtD
Pyrazinamide—XDH—Oxidative Stress—SOD2—osteoporosis	0.00103	0.0226	CbGpPWpGaD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—ACP5—osteoporosis	0.00102	0.0225	CbGpPWpGaD
Pyrazinamide—Anorexia—Calcium Acetate—osteoporosis	0.000993	0.00821	CcSEcCtD
Pyrazinamide—XDH—Oxidative Stress—GPX1—osteoporosis	0.00098	0.0216	CbGpPWpGaD
Pyrazinamide—Dysuria—Estropipate—osteoporosis	0.000973	0.00804	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Alendronate—osteoporosis	0.000935	0.00773	CcSEcCtD
Pyrazinamide—AOX1—Tryptophan metabolism—CYP19A1—osteoporosis	0.000919	0.0202	CbGpPWpGaD
Pyrazinamide—XDH—Purine metabolism—GPX1—osteoporosis	0.000908	0.02	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Calcium Acetate—osteoporosis	0.000905	0.00749	CcSEcCtD
Pyrazinamide—Anorexia—Ergocalciferol—osteoporosis	0.000877	0.00725	CcSEcCtD
Pyrazinamide—Feeling abnormal—Calcium Acetate—osteoporosis	0.000858	0.0071	CcSEcCtD
Pyrazinamide—Decreased appetite—Ergocalciferol—osteoporosis	0.0008	0.00661	CcSEcCtD
Pyrazinamide—Dysuria—Ethinyl Estradiol—osteoporosis	0.000788	0.00652	CcSEcCtD
Pyrazinamide—Hypersensitivity—Calcium Acetate—osteoporosis	0.000767	0.00634	CcSEcCtD
Pyrazinamide—Pruritus—Calcium Acetate—osteoporosis	0.000737	0.00609	CcSEcCtD
Pyrazinamide—Arthralgia—Etidronic acid—osteoporosis	0.000713	0.0059	CcSEcCtD
Pyrazinamide—Discomfort—Etidronic acid—osteoporosis	0.000705	0.00583	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Alendronate—osteoporosis	0.000662	0.00548	CcSEcCtD
Pyrazinamide—Vomiting—Calcium Acetate—osteoporosis	0.000662	0.00548	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Ibandronate—osteoporosis	0.000645	0.00533	CcSEcCtD
Pyrazinamide—Malaise—Alendronate—osteoporosis	0.000644	0.00532	CcSEcCtD
Pyrazinamide—Dysuria—Conjugated Estrogens—osteoporosis	0.000643	0.00531	CcSEcCtD
Pyrazinamide—Malaise—Ibandronate—osteoporosis	0.000627	0.00518	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Etidronic acid—osteoporosis	0.000623	0.00515	CcSEcCtD
Pyrazinamide—Nausea—Calcium Acetate—osteoporosis	0.000619	0.00512	CcSEcCtD
Pyrazinamide—Arthralgia—Estropipate—osteoporosis	0.000617	0.0051	CcSEcCtD
Pyrazinamide—Myalgia—Estropipate—osteoporosis	0.000617	0.0051	CcSEcCtD
Pyrazinamide—Myalgia—Alendronate—osteoporosis	0.000608	0.00503	CcSEcCtD
Pyrazinamide—Dyspepsia—Etidronic acid—osteoporosis	0.000602	0.00498	CcSEcCtD
Pyrazinamide—Discomfort—Alendronate—osteoporosis	0.0006	0.00497	CcSEcCtD
Pyrazinamide—Myalgia—Raloxifene—osteoporosis	0.000598	0.00494	CcSEcCtD
Pyrazinamide—Arthralgia—Raloxifene—osteoporosis	0.000598	0.00494	CcSEcCtD
Pyrazinamide—Myalgia—Ibandronate—osteoporosis	0.000592	0.00489	CcSEcCtD
Pyrazinamide—Arthralgia—Ibandronate—osteoporosis	0.000592	0.00489	CcSEcCtD
Pyrazinamide—Discomfort—Ibandronate—osteoporosis	0.000585	0.00483	CcSEcCtD
Pyrazinamide—Myalgia—Calcitriol—osteoporosis	0.000579	0.00479	CcSEcCtD
Pyrazinamide—Discomfort—Calcitriol—osteoporosis	0.000572	0.00473	CcSEcCtD
Pyrazinamide—Feeling abnormal—Etidronic acid—osteoporosis	0.000563	0.00466	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Raloxifene—osteoporosis	0.000561	0.00464	CcSEcCtD
Pyrazinamide—Nausea—Ergocalciferol—osteoporosis	0.000546	0.00452	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Ethinyl Estradiol—osteoporosis	0.000545	0.00451	CcSEcCtD
Pyrazinamide—Urticaria—Etidronic acid—osteoporosis	0.000543	0.00449	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Estropipate—osteoporosis	0.000539	0.00446	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Alendronate—osteoporosis	0.000531	0.00439	CcSEcCtD
Pyrazinamide—Malaise—Ethinyl Estradiol—osteoporosis	0.00053	0.00438	CcSEcCtD
Pyrazinamide—Anorexia—Calcitriol—osteoporosis	0.000529	0.00438	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.000522	0.00432	CcSEcCtD
Pyrazinamide—Dyspepsia—Estropipate—osteoporosis	0.000521	0.00431	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.000517	0.00427	CcSEcCtD
Pyrazinamide—Dyspepsia—Alendronate—osteoporosis	0.000513	0.00424	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Estropipate—osteoporosis	0.000511	0.00422	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.000506	0.00418	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Pamidronate—osteoporosis	0.000505	0.00418	CcSEcCtD
Pyrazinamide—Dyspepsia—Raloxifene—osteoporosis	0.000504	0.00417	CcSEcCtD
Pyrazinamide—Hypersensitivity—Etidronic acid—osteoporosis	0.000504	0.00417	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Estradiol—osteoporosis	0.000502	0.00415	CcSEcCtD
Pyrazinamide—Dyspepsia—Ibandronate—osteoporosis	0.000499	0.00413	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000495	0.00409	CcSEcCtD
Pyrazinamide—Discomfort—Ethinyl Estradiol—osteoporosis	0.000494	0.00409	CcSEcCtD
Pyrazinamide—Decreased appetite—Ibandronate—osteoporosis	0.000493	0.00408	CcSEcCtD
Pyrazinamide—Malaise—Pamidronate—osteoporosis	0.000491	0.00406	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00049	0.00405	CcSEcCtD
Pyrazinamide—Arthralgia—Risedronate—osteoporosis	0.000488	0.00403	CcSEcCtD
Pyrazinamide—Myalgia—Risedronate—osteoporosis	0.000488	0.00403	CcSEcCtD
Pyrazinamide—Pruritus—Etidronic acid—osteoporosis	0.000484	0.004	CcSEcCtD
Pyrazinamide—Decreased appetite—Calcitriol—osteoporosis	0.000483	0.00399	CcSEcCtD
Pyrazinamide—Feeling abnormal—Alendronate—osteoporosis	0.00048	0.00397	CcSEcCtD
Pyrazinamide—Urticaria—Estropipate—osteoporosis	0.00047	0.00389	CcSEcCtD
Pyrazinamide—Body temperature increased—Estropipate—osteoporosis	0.000468	0.00387	CcSEcCtD
Pyrazinamide—Feeling abnormal—Ibandronate—osteoporosis	0.000467	0.00387	CcSEcCtD
Pyrazinamide—Arthralgia—Pamidronate—osteoporosis	0.000464	0.00383	CcSEcCtD
Pyrazinamide—Myalgia—Pamidronate—osteoporosis	0.000464	0.00383	CcSEcCtD
Pyrazinamide—Urticaria—Alendronate—osteoporosis	0.000463	0.00383	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Zoledronate—osteoporosis	0.000461	0.00382	CcSEcCtD
Pyrazinamide—Body temperature increased—Alendronate—osteoporosis	0.000461	0.00381	CcSEcCtD
Pyrazinamide—Discomfort—Pamidronate—osteoporosis	0.000458	0.00379	CcSEcCtD
Pyrazinamide—XDH—Nucleotide metabolism—GPX1—osteoporosis	0.000456	0.01	CbGpPWpGaD
Pyrazinamide—Body temperature increased—Raloxifene—osteoporosis	0.000453	0.00375	CcSEcCtD
Pyrazinamide—Urticaria—Ibandronate—osteoporosis	0.000451	0.00373	CcSEcCtD
Pyrazinamide—Malaise—Zoledronate—osteoporosis	0.000448	0.00371	CcSEcCtD
Pyrazinamide—Body temperature increased—Ibandronate—osteoporosis	0.000448	0.00371	CcSEcCtD
Pyrazinamide—Urticaria—Calcitriol—osteoporosis	0.000441	0.00365	CcSEcCtD
Pyrazinamide—Hepatitis—Estradiol—osteoporosis	0.00044	0.00364	CcSEcCtD
Pyrazinamide—Body temperature increased—Calcitriol—osteoporosis	0.000439	0.00363	CcSEcCtD
Pyrazinamide—Hypersensitivity—Estropipate—osteoporosis	0.000436	0.0036	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Pamidronate—osteoporosis	0.000435	0.0036	CcSEcCtD
Pyrazinamide—Vomiting—Etidronic acid—osteoporosis	0.000435	0.00359	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—SOD2—osteoporosis	0.000434	0.00956	CbGpPWpGaD
Pyrazinamide—Rash—Etidronic acid—osteoporosis	0.000431	0.00356	CcSEcCtD
Pyrazinamide—Dermatitis—Etidronic acid—osteoporosis	0.000431	0.00356	CcSEcCtD
Pyrazinamide—Hypersensitivity—Alendronate—osteoporosis	0.000429	0.00355	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000426	0.00352	CcSEcCtD
Pyrazinamide—Anorexia—Pamidronate—osteoporosis	0.000424	0.0035	CcSEcCtD
Pyrazinamide—Myalgia—Zoledronate—osteoporosis	0.000423	0.0035	CcSEcCtD
Pyrazinamide—Arthralgia—Zoledronate—osteoporosis	0.000423	0.0035	CcSEcCtD
Pyrazinamide—Pruritus—Estropipate—osteoporosis	0.000418	0.00346	CcSEcCtD
Pyrazinamide—Discomfort—Zoledronate—osteoporosis	0.000418	0.00346	CcSEcCtD
Pyrazinamide—Hypersensitivity—Ibandronate—osteoporosis	0.000418	0.00346	CcSEcCtD
Pyrazinamide—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—osteoporosis	0.000415	0.00913	CbGpPWpGaD
Pyrazinamide—XDH—Selenium Micronutrient Network—GPX1—osteoporosis	0.000414	0.00912	CbGpPWpGaD
Pyrazinamide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000414	0.00342	CcSEcCtD
Pyrazinamide—Pruritus—Alendronate—osteoporosis	0.000412	0.00341	CcSEcCtD
Pyrazinamide—Dyspepsia—Risedronate—osteoporosis	0.000411	0.0034	CcSEcCtD
Pyrazinamide—Hypersensitivity—Calcitriol—osteoporosis	0.000409	0.00338	CcSEcCtD
Pyrazinamide—Arthralgia—Conjugated Estrogens—osteoporosis	0.000408	0.00337	CcSEcCtD
Pyrazinamide—Myalgia—Conjugated Estrogens—osteoporosis	0.000408	0.00337	CcSEcCtD
Pyrazinamide—Nausea—Etidronic acid—osteoporosis	0.000406	0.00336	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000405	0.00335	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000404	0.00334	CcSEcCtD
Pyrazinamide—Pruritus—Ibandronate—osteoporosis	0.000401	0.00332	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Zoledronate—osteoporosis	0.000397	0.00329	CcSEcCtD
Pyrazinamide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000395	0.00327	CcSEcCtD
Pyrazinamide—Pruritus—Calcitriol—osteoporosis	0.000393	0.00325	CcSEcCtD
Pyrazinamide—Dyspepsia—Pamidronate—osteoporosis	0.000391	0.00323	CcSEcCtD
Pyrazinamide—Anorexia—Zoledronate—osteoporosis	0.000387	0.0032	CcSEcCtD
Pyrazinamide—Decreased appetite—Pamidronate—osteoporosis	0.000386	0.00319	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000384	0.00317	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000382	0.00841	CbGpPWpGaD
Pyrazinamide—Urticaria—Ethinyl Estradiol—osteoporosis	0.000381	0.00315	CcSEcCtD
Pyrazinamide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000379	0.00313	CcSEcCtD
Pyrazinamide—Vomiting—Estropipate—osteoporosis	0.000376	0.00311	CcSEcCtD
Pyrazinamide—Rash—Estropipate—osteoporosis	0.000373	0.00308	CcSEcCtD
Pyrazinamide—Dermatitis—Estropipate—osteoporosis	0.000373	0.00308	CcSEcCtD
Pyrazinamide—Anorexia—Conjugated Estrogens—osteoporosis	0.000373	0.00308	CcSEcCtD
Pyrazinamide—Urticaria—Risedronate—osteoporosis	0.000371	0.00307	CcSEcCtD
Pyrazinamide—Vomiting—Alendronate—osteoporosis	0.00037	0.00306	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00037	0.00306	CcSEcCtD
Pyrazinamide—Body temperature increased—Risedronate—osteoporosis	0.00037	0.00306	CcSEcCtD
Pyrazinamide—Rash—Alendronate—osteoporosis	0.000367	0.00304	CcSEcCtD
Pyrazinamide—Dermatitis—Alendronate—osteoporosis	0.000367	0.00303	CcSEcCtD
Pyrazinamide—Feeling abnormal—Pamidronate—osteoporosis	0.000366	0.00303	CcSEcCtD
Pyrazinamide—Vomiting—Raloxifene—osteoporosis	0.000364	0.00301	CcSEcCtD
Pyrazinamide—Rash—Raloxifene—osteoporosis	0.000361	0.00299	CcSEcCtD
Pyrazinamide—Dermatitis—Raloxifene—osteoporosis	0.000361	0.00298	CcSEcCtD
Pyrazinamide—Vomiting—Ibandronate—osteoporosis	0.000361	0.00298	CcSEcCtD
Pyrazinamide—Rash—Ibandronate—osteoporosis	0.000358	0.00296	CcSEcCtD
Pyrazinamide—Dermatitis—Ibandronate—osteoporosis	0.000357	0.00295	CcSEcCtD
Pyrazinamide—Dyspepsia—Zoledronate—osteoporosis	0.000357	0.00295	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000356	0.00294	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Estradiol—osteoporosis	0.000356	0.00294	CcSEcCtD
Pyrazinamide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000353	0.00292	CcSEcCtD
Pyrazinamide—Vomiting—Calcitriol—osteoporosis	0.000353	0.00292	CcSEcCtD
Pyrazinamide—Decreased appetite—Zoledronate—osteoporosis	0.000353	0.00292	CcSEcCtD
Pyrazinamide—Nausea—Estropipate—osteoporosis	0.000351	0.00291	CcSEcCtD
Pyrazinamide—Body temperature increased—Pamidronate—osteoporosis	0.000351	0.0029	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00035	0.0029	CcSEcCtD
Pyrazinamide—Rash—Calcitriol—osteoporosis	0.00035	0.00289	CcSEcCtD
Pyrazinamide—Dermatitis—Calcitriol—osteoporosis	0.00035	0.00289	CcSEcCtD
Pyrazinamide—Nausea—Alendronate—osteoporosis	0.000346	0.00286	CcSEcCtD
Pyrazinamide—Malaise—Estradiol—osteoporosis	0.000346	0.00286	CcSEcCtD
Pyrazinamide—Hypersensitivity—Risedronate—osteoporosis	0.000344	0.00285	CcSEcCtD
Pyrazinamide—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000344	0.00284	CcSEcCtD
Pyrazinamide—Nausea—Raloxifene—osteoporosis	0.00034	0.00281	CcSEcCtD
Pyrazinamide—Decreased appetite—Conjugated Estrogens—osteoporosis	0.00034	0.00281	CcSEcCtD
Pyrazinamide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000339	0.0028	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000337	0.00279	CcSEcCtD
Pyrazinamide—Nausea—Ibandronate—osteoporosis	0.000337	0.00279	CcSEcCtD
Pyrazinamide—Feeling abnormal—Zoledronate—osteoporosis	0.000334	0.00277	CcSEcCtD
Pyrazinamide—Pruritus—Risedronate—osteoporosis	0.000331	0.00273	CcSEcCtD
Pyrazinamide—CYP1A2—Estrogen Receptor Pathway—ESR1—osteoporosis	0.00033	0.00726	CbGpPWpGaD
Pyrazinamide—Nausea—Calcitriol—osteoporosis	0.00033	0.00273	CcSEcCtD
Pyrazinamide—Hypersensitivity—Pamidronate—osteoporosis	0.000327	0.00271	CcSEcCtD
Pyrazinamide—Myalgia—Estradiol—osteoporosis	0.000326	0.0027	CcSEcCtD
Pyrazinamide—Arthralgia—Estradiol—osteoporosis	0.000326	0.0027	CcSEcCtD
Pyrazinamide—Urticaria—Zoledronate—osteoporosis	0.000322	0.00267	CcSEcCtD
Pyrazinamide—Discomfort—Estradiol—osteoporosis	0.000322	0.00267	CcSEcCtD
Pyrazinamide—Body temperature increased—Zoledronate—osteoporosis	0.000321	0.00265	CcSEcCtD
Pyrazinamide—Pruritus—Pamidronate—osteoporosis	0.000314	0.0026	CcSEcCtD
Pyrazinamide—Urticaria—Conjugated Estrogens—osteoporosis	0.00031	0.00257	CcSEcCtD
Pyrazinamide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000309	0.00255	CcSEcCtD
Pyrazinamide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000305	0.00252	CcSEcCtD
Pyrazinamide—Rash—Ethinyl Estradiol—osteoporosis	0.000302	0.0025	CcSEcCtD
Pyrazinamide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000302	0.0025	CcSEcCtD
Pyrazinamide—Hypersensitivity—Zoledronate—osteoporosis	0.000299	0.00247	CcSEcCtD
Pyrazinamide—Vomiting—Risedronate—osteoporosis	0.000297	0.00246	CcSEcCtD
Pyrazinamide—Rash—Risedronate—osteoporosis	0.000295	0.00244	CcSEcCtD
Pyrazinamide—Dermatitis—Risedronate—osteoporosis	0.000294	0.00243	CcSEcCtD
Pyrazinamide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000288	0.00238	CcSEcCtD
Pyrazinamide—Pruritus—Zoledronate—osteoporosis	0.000287	0.00237	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000285	0.00236	CcSEcCtD
Pyrazinamide—Nausea—Ethinyl Estradiol—osteoporosis	0.000285	0.00235	CcSEcCtD
Pyrazinamide—Vomiting—Pamidronate—osteoporosis	0.000283	0.00234	CcSEcCtD
Pyrazinamide—Rash—Pamidronate—osteoporosis	0.00028	0.00232	CcSEcCtD
Pyrazinamide—Dermatitis—Pamidronate—osteoporosis	0.00028	0.00231	CcSEcCtD
Pyrazinamide—Nausea—Risedronate—osteoporosis	0.000278	0.0023	CcSEcCtD
Pyrazinamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000277	0.00609	CbGpPWpGaD
Pyrazinamide—Pruritus—Conjugated Estrogens—osteoporosis	0.000276	0.00229	CcSEcCtD
Pyrazinamide—Dyspepsia—Estradiol—osteoporosis	0.000275	0.00228	CcSEcCtD
Pyrazinamide—CYP1A2—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000273	0.00601	CbGpPWpGaD
Pyrazinamide—Decreased appetite—Estradiol—osteoporosis	0.000272	0.00225	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Estradiol—osteoporosis	0.00027	0.00223	CcSEcCtD
Pyrazinamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000269	0.00592	CbGpPWpGaD
Pyrazinamide—Nausea—Pamidronate—osteoporosis	0.000264	0.00218	CcSEcCtD
Pyrazinamide—Vomiting—Zoledronate—osteoporosis	0.000258	0.00213	CcSEcCtD
Pyrazinamide—Feeling abnormal—Estradiol—osteoporosis	0.000258	0.00213	CcSEcCtD
Pyrazinamide—Rash—Zoledronate—osteoporosis	0.000256	0.00212	CcSEcCtD
Pyrazinamide—Dermatitis—Zoledronate—osteoporosis	0.000256	0.00211	CcSEcCtD
Pyrazinamide—Vomiting—Conjugated Estrogens—osteoporosis	0.000248	0.00205	CcSEcCtD
Pyrazinamide—Urticaria—Estradiol—osteoporosis	0.000248	0.00205	CcSEcCtD
Pyrazinamide—Body temperature increased—Estradiol—osteoporosis	0.000247	0.00204	CcSEcCtD
Pyrazinamide—Rash—Conjugated Estrogens—osteoporosis	0.000246	0.00204	CcSEcCtD
Pyrazinamide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000246	0.00204	CcSEcCtD
Pyrazinamide—Nausea—Zoledronate—osteoporosis	0.000241	0.00199	CcSEcCtD
Pyrazinamide—Nausea—Conjugated Estrogens—osteoporosis	0.000232	0.00192	CcSEcCtD
Pyrazinamide—Hypersensitivity—Estradiol—osteoporosis	0.00023	0.00191	CcSEcCtD
Pyrazinamide—XDH—Selenium Micronutrient Network—IL1B—osteoporosis	0.000227	0.00499	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000224	0.00494	CbGpPWpGaD
Pyrazinamide—Pruritus—Estradiol—osteoporosis	0.000221	0.00183	CcSEcCtD
Pyrazinamide—AOX1—Disease—PKM—osteoporosis	0.000217	0.00477	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—SOST—osteoporosis	0.000217	0.00477	CbGpPWpGaD
Pyrazinamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000214	0.0047	CbGpPWpGaD
Pyrazinamide—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000211	0.00464	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PGLS—osteoporosis	0.000205	0.00452	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ANTXR2—osteoporosis	0.000205	0.00452	CbGpPWpGaD
Pyrazinamide—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000201	0.00443	CbGpPWpGaD
Pyrazinamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.0002	0.0044	CbGpPWpGaD
Pyrazinamide—Vomiting—Estradiol—osteoporosis	0.000199	0.00164	CcSEcCtD
Pyrazinamide—Rash—Estradiol—osteoporosis	0.000197	0.00163	CcSEcCtD
Pyrazinamide—Dermatitis—Estradiol—osteoporosis	0.000197	0.00163	CcSEcCtD
Pyrazinamide—Nausea—Estradiol—osteoporosis	0.000186	0.00154	CcSEcCtD
Pyrazinamide—AOX1—Metabolism—PKM—osteoporosis	0.000181	0.00399	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—FDPS—osteoporosis	0.000181	0.00399	CbGpPWpGaD
Pyrazinamide—CYP1A2—Tryptophan metabolism—CYP19A1—osteoporosis	0.00018	0.00396	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—GSN—osteoporosis	0.000175	0.00384	CbGpPWpGaD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000173	0.00381	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PGLS—osteoporosis	0.000172	0.00379	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GPD2—osteoporosis	0.000172	0.00379	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PKM—osteoporosis	0.000169	0.00371	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—FDPS—osteoporosis	0.000169	0.00371	CbGpPWpGaD
Pyrazinamide—XDH—Selenium Micronutrient Network—TNF—osteoporosis	0.000165	0.00362	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PGLS—osteoporosis	0.00016	0.00352	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GPD2—osteoporosis	0.00016	0.00352	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ATIC—osteoporosis	0.000157	0.00346	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PNP—osteoporosis	0.000157	0.00346	CbGpPWpGaD
Pyrazinamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000154	0.0034	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—LRP5—osteoporosis	0.000152	0.00334	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ATIC—osteoporosis	0.000146	0.00322	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PNP—osteoporosis	0.000146	0.00322	CbGpPWpGaD
Pyrazinamide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000145	0.0032	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—LRP6—osteoporosis	0.000145	0.0032	CbGpPWpGaD
Pyrazinamide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000143	0.00316	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—LTF—osteoporosis	0.00014	0.00307	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—RPL24—osteoporosis	0.00014	0.00307	CbGpPWpGaD
Pyrazinamide—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000139	0.00305	CbGpPWpGaD
Pyrazinamide—CYP1A2—Arachidonic acid metabolism—GPX1—osteoporosis	0.000137	0.00301	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—OXCT1—osteoporosis	0.000134	0.00294	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CA2—osteoporosis	0.000134	0.00294	CbGpPWpGaD
Pyrazinamide—XDH—Selenium Micronutrient Network—IL6—osteoporosis	0.000133	0.00292	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—MGLL—osteoporosis	0.00013	0.00287	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CA2—osteoporosis	0.000124	0.00274	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—OXCT1—osteoporosis	0.000124	0.00274	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—MGLL—osteoporosis	0.000121	0.00267	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ACP5—osteoporosis	0.000121	0.00266	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	0.00012	0.00264	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—CYP27A1—osteoporosis	0.000119	0.00262	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000118	0.00259	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—CYP27A1—osteoporosis	0.000118	0.00259	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—TPI1—osteoporosis	0.000113	0.00248	CbGpPWpGaD
Pyrazinamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000112	0.00247	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—IDH2—osteoporosis	0.000111	0.00244	CbGpPWpGaD
Pyrazinamide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000111	0.00244	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—P4HB—osteoporosis	0.000106	0.00233	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CYP27A1—osteoporosis	0.000104	0.00229	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—GAPDH—osteoporosis	0.000104	0.00229	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—IDH2—osteoporosis	0.000103	0.00227	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ACP5—osteoporosis	0.000101	0.00223	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—NFATC1—osteoporosis	9.87e-05	0.00217	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—DKK1—osteoporosis	9.79e-05	0.00215	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CYP27A1—osteoporosis	9.69e-05	0.00213	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—WNT1—osteoporosis	9.43e-05	0.00208	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—TPI1—osteoporosis	9.42e-05	0.00207	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ACP5—osteoporosis	9.42e-05	0.00207	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	9.19e-05	0.00202	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—FGA—osteoporosis	9.17e-05	0.00202	CbGpPWpGaD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	9.09e-05	0.002	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	9.07e-05	0.002	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—P4HB—osteoporosis	8.86e-05	0.00195	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—TPI1—osteoporosis	8.76e-05	0.00193	CbGpPWpGaD
Pyrazinamide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	8.73e-05	0.00192	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GAPDH—osteoporosis	8.7e-05	0.00191	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—RAP1A—osteoporosis	8.47e-05	0.00186	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—P4HB—osteoporosis	8.24e-05	0.00181	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ENO1—osteoporosis	8.18e-05	0.0018	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GAPDH—osteoporosis	8.08e-05	0.00178	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PSMA5—osteoporosis	8.06e-05	0.00177	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—PSMA2—osteoporosis	8.06e-05	0.00177	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoporosis	8.02e-05	0.00176	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	7.97e-05	0.00175	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—RAP1A—osteoporosis	7.87e-05	0.00173	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	7.55e-05	0.00166	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—CALCA—osteoporosis	7.51e-05	0.00165	CbGpPWpGaD
Pyrazinamide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7.08e-05	0.00156	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ENO1—osteoporosis	6.85e-05	0.00151	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—KL—osteoporosis	6.82e-05	0.0015	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PSMA2—osteoporosis	6.75e-05	0.00149	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—PSMA5—osteoporosis	6.75e-05	0.00149	CbGpPWpGaD
Pyrazinamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	6.74e-05	0.00148	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ENO1—osteoporosis	6.37e-05	0.0014	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PSMA2—osteoporosis	6.27e-05	0.00138	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—PSMA5—osteoporosis	6.27e-05	0.00138	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—CYP19A1—osteoporosis	6.26e-05	0.00138	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	6.24e-05	0.00137	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	6.23e-05	0.00137	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metapathway biotransformation—CYP19A1—osteoporosis	6.17e-05	0.00136	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.87e-05	0.00129	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	5.82e-05	0.00128	CbGpPWpGaD
Pyrazinamide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	5.82e-05	0.00128	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.72e-05	0.00126	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—CYP19A1—osteoporosis	5.47e-05	0.0012	CbGpPWpGaD
Pyrazinamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.46e-05	0.0012	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—ADCY5—osteoporosis	5.34e-05	0.00118	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—CYP19A1—osteoporosis	5.09e-05	0.00112	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MTHFR—osteoporosis	4.91e-05	0.00108	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	4.83e-05	0.00106	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	4.76e-05	0.00105	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—IRS2—osteoporosis	4.67e-05	0.00103	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.57e-05	0.00101	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—ADCY5—osteoporosis	4.47e-05	0.000984	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—GPX1—osteoporosis	4.46e-05	0.000981	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—ADCY5—osteoporosis	4.16e-05	0.000915	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—GPX1—osteoporosis	4.14e-05	0.000912	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—MTHFR—osteoporosis	4.11e-05	0.000905	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—IRS1—osteoporosis	4.08e-05	0.000898	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.89e-05	0.000856	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—IL6R—osteoporosis	3.83e-05	0.000843	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—MTHFR—osteoporosis	3.82e-05	0.000842	CbGpPWpGaD
Pyrazinamide—CYP1A2—Biological oxidations—POMC—osteoporosis	3.76e-05	0.000828	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PKM—osteoporosis	3.55e-05	0.000781	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—FDPS—osteoporosis	3.55e-05	0.000781	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GPD2—osteoporosis	3.36e-05	0.00074	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PGLS—osteoporosis	3.36e-05	0.00074	CbGpPWpGaD
Pyrazinamide—AOX1—Metabolism—POMC—osteoporosis	3.29e-05	0.000724	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PNP—osteoporosis	3.08e-05	0.000677	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ATIC—osteoporosis	3.08e-05	0.000677	CbGpPWpGaD
Pyrazinamide—XDH—Metabolism—POMC—osteoporosis	3.06e-05	0.000673	CbGpPWpGaD
Pyrazinamide—CYP3A4—Biological oxidations—POMC—osteoporosis	2.9e-05	0.000639	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PKM—osteoporosis	2.74e-05	0.000603	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—FDPS—osteoporosis	2.74e-05	0.000603	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—OXCT1—osteoporosis	2.62e-05	0.000576	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CA2—osteoporosis	2.62e-05	0.000576	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GPD2—osteoporosis	2.6e-05	0.000571	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PGLS—osteoporosis	2.6e-05	0.000571	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—MGLL—osteoporosis	2.55e-05	0.000561	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.4e-05	0.000529	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PNP—osteoporosis	2.37e-05	0.000523	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ATIC—osteoporosis	2.37e-05	0.000523	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—MYC—osteoporosis	2.27e-05	0.0005	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—TGFB1—osteoporosis	2.27e-05	0.000499	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—IDH2—osteoporosis	2.17e-05	0.000477	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CYP27A1—osteoporosis	2.04e-05	0.000448	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CA2—osteoporosis	2.02e-05	0.000444	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—OXCT1—osteoporosis	2.02e-05	0.000444	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ACP5—osteoporosis	1.98e-05	0.000436	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—MGLL—osteoporosis	1.97e-05	0.000433	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.96e-05	0.000431	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—TPI1—osteoporosis	1.84e-05	0.000406	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—P4HB—osteoporosis	1.73e-05	0.000381	CbGpPWpGaD
Pyrazinamide—AOX1—Disease—IL6—osteoporosis	1.71e-05	0.000376	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GAPDH—osteoporosis	1.7e-05	0.000374	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—IDH2—osteoporosis	1.67e-05	0.000368	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—RAP1A—osteoporosis	1.66e-05	0.000365	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.57e-05	0.000346	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ACP5—osteoporosis	1.53e-05	0.000337	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.44e-05	0.000318	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—TPI1—osteoporosis	1.42e-05	0.000313	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ENO1—osteoporosis	1.34e-05	0.000295	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—P4HB—osteoporosis	1.34e-05	0.000294	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PSMA5—osteoporosis	1.32e-05	0.00029	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—PSMA2—osteoporosis	1.32e-05	0.00029	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GAPDH—osteoporosis	1.31e-05	0.000289	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—RAP1A—osteoporosis	1.28e-05	0.000281	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—CYP19A1—osteoporosis	1.07e-05	0.000236	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ENO1—osteoporosis	1.03e-05	0.000227	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PSMA2—osteoporosis	1.02e-05	0.000224	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—PSMA5—osteoporosis	1.02e-05	0.000224	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—ADCY5—osteoporosis	8.74e-06	0.000192	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—GPX1—osteoporosis	8.71e-06	0.000192	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—CYP19A1—osteoporosis	8.26e-06	0.000182	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—MTHFR—osteoporosis	8.04e-06	0.000177	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—ADCY5—osteoporosis	6.75e-06	0.000149	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—GPX1—osteoporosis	6.73e-06	0.000148	CbGpPWpGaD
Pyrazinamide—CYP1A2—Metabolism—POMC—osteoporosis	6.43e-06	0.000142	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—MTHFR—osteoporosis	6.21e-06	0.000137	CbGpPWpGaD
Pyrazinamide—CYP3A4—Metabolism—POMC—osteoporosis	4.96e-06	0.000109	CbGpPWpGaD
